Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elan to spin off drug discovery business into Neotope; complete, now called Prothena

Executive Summary

Elan Corp. PLC (neurodegenerative and autoimmune diseases) is planning to spin off its discovery science business into Neotope Biosciences PLC, which will be an independent publicly traded company in the US. Elan will invest $120-130mm in equity into the start-up for a 14-18% stake; it anticipates completing the transaction by the end of this year.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Spin-Off

Related Companies